Research Article
Autoimmune Diseases Induced or Exacerbated by COVID-19: A Single Center Experience
Table 1
Demographic and clinical characteristics of cases of post-COVID-19 autoimmune diseases
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
F, female; M, male; P, patient; NA, data are not available; PCR, polymerase chain reaction; HSP, Henöch–Schönlein purpura; ITP, idiopathic thrombocytopenic purpura; GPA, granulomatosis with polyangiitis. Time since diagnosis was calculated from the first positive nasopharyngeal swab or the suspected initiation of symptoms (the earlier). Laboratory reference normal ranges: CRP: 0–0.5 mg/dL; c-ANCA: <10 U/mL; ESR: 1–20 mm/h. |